Drug Trial Radar · NCT00509106
Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia
Last checked: Nov 19, 2026Latest source record: Mar 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
622
Actual
Start
Jul 2007
Primary completion
Aug 2008
Study completion Jun 2009
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jul 31, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine if the antibiotic ceftaroline is safe and effective in the treatment of community-acquired pneumonia in adults.
Conditions
- Bacterial Pneumonia
Interventions
Ceftaroline fosamil for InjectionDrug
2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
CeftriaxoneDrug
1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days
PlaceboDrug
Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at the Test of Cure (TOC) in the Modified Intent to Treat Efficacy (MITTE) PopulationTime frame: 8-15 days after last dose of study drug
- Clinical Cure Rate for Ceftaroline Compared With That for Ceftriaxone at TOC in the Clinically Evaluable (CE) PopulationTime frame: 8-15 days after last dose of study drug
Locations
134 sites in 15 countries. Site status is shown where the registry gives one.
Investigational Site
Durham, North Carolina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Invetigational Site
Buenos Aires, Argentina
Investigational Site
Córdoba, Argentina
Investigational Site
Córdoba, Argentina
INvestigational Site
Córdoba, Argentina
Investigational Site
Córdoba, Argentina
Investigational Site
Entre Ríos, Argentina
Investigational Site
Granadero Baiggoria, Argentina
Investigational Site
Paraná, Argentina
Investigational Site
Santa Fe, Argentina
Investigational Site
Santa Fe, Argentina
Investigational Site
Autonoma, Buenos Aires, Argentina
Investigational Site
Mar del Plata, Buenos Aires, Argentina
Investigational Site
Merlo, Buenos Aires, Argentina
Investigational Site
Córdoba, Córdoba Province, Argentina
Investigational Site
Steyr, Austria
Investigational Site
Vienna, Austria
Investigational Site
Wels, Austria
Investigational site
Grieskirchner, Wels, Austria
Investigational Site
Plovdiv, Bulgaria
Investigational Site
Rousse, Bulgaria
Investigational Site
Sofia, Bulgaria
Investigational Site
Sofia, Bulgaria
Investigational Site
Sofia, Bulgaria
Investigational Site
Sofia, Bulgaria
Investigational Drug
Varna, Bulgaria
Investigational Site
Santiago, Chile
Investigational Site
Santiago, Chile
Investigational Site
Santiago, Chile
Investigational Site
Talcahuano, Chile
Investigational Site
Temuco, Chile
Inestigational Site
Valdivia, Chile
Showing 40 of 134 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.